Overview

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital